Consort Medical plc (CSRMY) Upgraded at Zacks Investment Research

Consort Medical plc (NASDAQ:CSRMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm currently has a $16.00 price target on the stock.

According to Zacks, “Consort Medical Plc engages in the design, development, manufacture and sale of medical drug delivery devices. It operates through the Bespak and Aesica segments. Bespak segment develops and produces drug delivery devices which serves pharmaceutical companies with inhaler and auto-injector technologies. Aesica segment is a contract development and manufacturing organization which serves pharmaceutical firms with active pharmaceutical ingredient and finished dose formulation development and manufacturing services. Consort Medical Plc is headquartered in Hemel Hempstead, United Kingdom. “

Shares of Consort Medical plc (CSRMY) remained flat at $13.85 during midday trading on Friday. The company has a market capitalization of $676.61 million and a price-to-earnings ratio of 28.27. Consort Medical plc has a 52 week low of $12.90 and a 52 week high of $14.50. The company has a 50 day moving average of $13.58 and a 200 day moving average of $13.28.

TRADEMARK VIOLATION WARNING: “Consort Medical plc (CSRMY) Upgraded at Zacks Investment Research” was first published by sleekmoney and is owned by of sleekmoney. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://sleekmoney.com/consort-medical-plc-csrmy-upgraded-at-zacks-investment-research/1916132.html.

About Consort Medical plc

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Get a free copy of the Zacks research report on Consort Medical plc (CSRMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/consort-medical-plc-csrmy-upgraded-at-zacks-investment-research/1916132.html

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *